BioArctic stock
Price history
+5.70% over the period1 year: from kr 284.40 (November 20, 2025) to kr 300.60 (November 20, 2026), +5.70%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 300.60 |
| October 30, 2026 | kr 317.20 |
| September 30, 2026 | kr 310.40 |
| August 31, 2026 | kr 318.40 |
| July 31, 2026 | kr 325.00 |
| June 30, 2026 | kr 329.20 |
| May 29, 2026 | kr 352.40 |
| April 30, 2026 | kr 323.80 |
| March 31, 2026 | kr 320.00 |
| February 27, 2026 | kr 308.80 |
| January 30, 2026 | kr 319.00 |
| December 30, 2025 | kr 310.80 |
| November 28, 2025 | kr 304.60 |
| November 20, 2025 | kr 284.40 |
At a glance
The company
Develops biological drugs, primarily antibodies, for central nervous system disorders including Alzheimer's, Parkinson's and ALS
Latest results
Quarter to June 30, 2026 · EPS -kr 0.13 (estimate -kr 0.77)
Next event
TickerLandia's take on BioArctic
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 26 vs a median of 95 over its last 5 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 259 vs 18 (+1,331%) in a group of 9.
- Strong point: Financial strength (75/100 in its group). Weak point: Earnings stability (36/100).
- “Below historical valuation” (Sweden): No. 2 of 4.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−17.51% from the 52-week high
Analysts · 3 analysts
Average targetkr 314.00+4.46% vs. price
Buy 2 · Hold 1 · Sell 0
TickerLandia Fingerprint: BioArctic
Compared with similar companies: very high price.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high88
How much it costs relative to what it produces.
Metric Value Position in group Price/book 13.5 82 EV/EBITDA 117.6 91 P/E (trailing 12 months) 259.5 99 Price/sales 27.1 78 Forward P/E 105.6 92 Profitabilityaverage53
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.6% 52 Gross margin 93.2% 81 Net margin 10.5% 50 ROE 5.2% 34 ROA 4.8% 47 Earnings stabilitylow36
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 252.8% 28 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthlow37
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −36.90% 11 Average revenue growth (3 years) +105.78% 85 Earnings growth (year over year) −111.93% 15 Financial strengthhigh75
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.04 68 Current ratio 3.99 61 Interest coverage 675.3 97 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.78 75 Dividendaverage56
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 1 year 30 Dividend yield 0.7% 42 Payout ratiopays out more than its earnings 169.5% 97 Market momentumaverage42
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average −5.01% 38 1-year return +5.70% 46 Riskaverage51
How much the price swings.
Metric Value Position in group Volatility (60 days) 29.4% 57 Maximum drawdown (12 months) 22.9% 45
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
BioArctic is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), BioArctic's P/E today is 26.1, below the median of its last 5 fiscal years (94.9; between 18.9 and 116.7 from 2017 to 2025). BioArctic's P/E (trailing 12 months): 259.5, +1,331% against the median of a group of 9 similar companies (18.1).
Compared with 9 similar companies
| Metric | BioArctic | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 259.5 | High | |
| Forward P/E | 105.6 | High | |
| Operating margin | 19.6% | Middle | |
| ROE | 5.2% | Low | |
| Debt/equity | 0.04 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: BioArctic. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 247.53M
Latest quarter · Q2 2026
Net income
-kr 11.17M
Latest quarter · Q2 2026
Quarterly net margin
-4.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 27.17B
- P/E
- 259.5
- EPS
- kr 1.18
- Volume
- 72.62K
- Daily trading
- €2.87M
- Dividend yield
- 0.67%
- Last ex-dividend on May 29, 2026
How BioArctic is changing
All resultsRevenue grew 98.3% a year on average over the last 5 years
Operating margin rose from −3.5% to 68.4%
Profits turn into cash: free cash flow equal to 128% of net income
Returns
BioArctic returns with dividends
kr 1,000 invested in BioArctic 5 years ago, on November 22, 2021, would be worth kr 2,515 today with dividends reinvested: +151.50% in total, +20.28% per year. On price alone it would be kr 2,501 (+150.08%).
| Period | BioArctic | kr 1,000 becomes |
|---|---|---|
| 1 month | +0.20% | kr 1,002 |
| 6 months | −6.59% | kr 934 |
| Year to date | −3.28% | kr 967 |
| 1 year | +6.30% | kr 1,063 |
| 3 years | +28.10% | kr 1,281 |
| 5 years | +151.50% | kr 2,515 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
BioArctic: technical analysis
BioArctic is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 20.4% below its all-time closing high (kr 377.80, June 12, 2023).
- Trend
- Downward
- RSI (14 sessions)
- 43
- Between 30 and 70
- vs 200-session average
- −5.01%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 16, 2026
Support and resistance
Price areas where BioArctic has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 327.35+8.90%4 touches, last on October 29, 2026
- Resistancekr 316.20+5.19%3 touches, last on November 10, 2026
- Resistancekr 304.12+1.17%5 touches, last on May 19, 2026
- Last pricekr 300.60
- Supportkr 292.27−2.77%3 touches, last on July 17, 2026
- Supportkr 284.70−5.29%4 touches, last on November 3, 2026
- Supportkr 276.70−7.95%2 touches, last on June 10, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 29.4%
- Largest fall in the last year
- −22.94%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
BioArctic: seasonality
Average monthly price change over 9 years
Over the last 9 years, the strongest month for BioArctic has been July: +38.59% on average, positive in 6 years out of 9. The weakest has been March: −9.95% on average, positive in 3 years out of 9. November, the current month, has been positive in 7 years out of 9 (+8.22% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.93% | +4.21% | 6 of 9 |
| February | −2.88% | −7.46% | 2 of 9 |
| March | −9.95% | −12.71% | 3 of 9 |
| April | +0.85% | +1.28% | 6 of 9 |
| May | +4.91% | +3.71% | 5 of 9 |
| June | +2.33% | −2.20% | 3 of 9 |
| July | +38.59% | +7.02% | 6 of 9 |
| August | +4.90% | +3.11% | 6 of 9 |
| September | +21.76% | −2.25% | 3 of 9 |
| October | −5.59% | −7.32% | 3 of 9 |
| November | +8.22% | +4.03% | 7 of 9 |
| December | +3.11% | +2.98% | 7 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
BioArctic and its competitors
Employing 150 people, the Stockholm-based biotech develops antibody drugs aimed at brain and nerve diseases. Its most advanced asset is lecanemab, which it offers as an intravenous treatment while developing a subcutaneous version, and a further lecanemab study is in Phase 3 testing for patients before symptoms appear. Other programmes target Alzheimer's, Parkinson's and ALS, and preclinical and research-stage projects cover additional central nervous system targets.
- Headquarters
- Stockholm, Sweden
- Employees
- 150
- Founded
- 2000
- Chief executive
- Gunilla Osswald
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BioArcticBIOA.B | $2.66B | 19.6% | 259.5 | −6.59% |
| Bavarian NordicBAVA | $2.72B | 18.1% | 12.7 | +24.00% |
| Zealand PharmaZEAL | $2.05B | 59.0% | 4.76 | −33.57% |
| Lakefront BiotherapeuticsLKFT | $2.19B | 57.5% | 2.53 | +29.28% |
| CamurusCAMX | $4.32B | 37.4% | 58.7 | +37.97% |
| IdorsiaIDIA | $1.26B | -68.4% | — | −10.26% |
Same industry or related industries, similar size. Compare BioArctic with its competitors · Full profile
